GLP-1s and birth control: product-specific precautions

At a glance

• Zepbound advises a non-oral method or added barrier contraception for four weeks after starting and each dose increase.
• Foundayo advises the corresponding precaution for 30 days after starting and each dose increase.
• Semaglutide labeling advises discontinuation at least two months before a planned pregnancy.

The oral-contraceptive warning now includes another product

Tirzepatide delays gastric emptying, and its label describes precautions for people relying on oral hormonal contraception. The current Foundayo label also includes oral-contraceptive guidance. Do not assume the issue disappears because a GLP-1 comes as a tablet.

For semaglutide, do not transfer another product’s exact contraceptive rule. Still discuss vomiting, diarrhea and the instructions for the contraceptive itself.

Sources: Wegovy prescribing informationZepbound prescribing informationFoundayo prescribing information

Make a plan before pregnancy

The semaglutide labels advise stopping at least two months before a planned pregnancy because of its long persistence in the body. Other agents have their own instructions. The clinician should plan how the underlying condition will be managed during the change.

If pregnancy is recognized during weight-management treatment, promptly contact the prescriber. Do not treat intentional weight loss in pregnancy as an extension of a pre-pregnancy program.

Sources: Wegovy prescribing informationZepbound prescribing informationFoundayo prescribing information

Breastfeeding requires formulation-specific advice

Lactation information differs between products and formulations and can change as new data arrive. Read the current label with a clinician who understands the infant’s needs, your condition and alternative treatment routes.

A small study or the absence of measured drug in a sample does not establish the safety of every formulation or combination of ingredients.

Sources: Wegovy prescribing informationZepbound prescribing informationFoundayo prescribing information

Sources and review boundaries

Source check dates are listed below. First-party pages support descriptions of a service’s public offer; medical references support the educational context. They do not establish an independent clinical audit of a provider. This is general education, not personal medical advice; no named licensed clinical reviewer has reviewed this article.

1. Wegovy prescribing informationMedical or regulatory source · Source reviewed · 2026-10-02
2. Zepbound prescribing informationMedical or regulatory source · Source reviewed · 2026-10-02
3. Foundayo prescribing informationMedical or regulatory source · Source reviewed · 2026-10-02